Rachele Bellini
Perugia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy.
Journal: Biochemistry and biophysics reports
Published: May 11, 2026
Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis.
Journal: Biochemical pharmacology
Published: February 07, 2025
Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: September 20, 2024
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4-/- Mice.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: September 06, 2024
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases.
Journal: Pharmacological research
Published: July 24, 2024
Analysis of Oral and Gut Microbiota Composition in Children with Dental Caries by NGS Approaches.
Journal: Recent advances in inflammation & allergy drug discovery
Published: June 03, 2024
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.
Journal: Biochemical pharmacology
Published: December 04, 2023
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
Journal: Journal of the American Heart Association
Published: November 24, 2023
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: October 14, 2023
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease.
Journal: Biochemical pharmacology
Published: August 29, 2023
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma.
Journal: Frontiers in oncology
Published: January 09, 2023
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH.
Journal: Scientific reports
Published: October 25, 2022
Last Updated: 09/26/2026